[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341299-105":59,"doc-detail-341299-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pan-cancer-analysis-of-dctn2-and-its-tumour-promoting-role-in-hcc-abstract","Pan-cancer analysis of DCTN2 and its tumour-promoting role in HCC - Abstract","","Dynactin subunit 2 (DCTN2) contributes to tumour progression across cancers, yet its mechanisms and links to the tumour immune microenvironment remain unclear. This study integrates analyses across major cancer databases to define DCTN2 expression and function. DCTN2 is elevated in tumour tissues and associates with poor patient outcomes. Gene Set Enrichment Analysis links higher DCTN2 to oncogenic pathways and reduced anti-tumour immune signalling. Functional studies in hepatocellular carcinoma show that DCTN2 knockdown suppresses proliferation and metastasis by modulating the AKT pathway, with rescue effects upon AKT activation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-of-dctn2-and-its-tumour-promoting-role-in-hcc-abstract/341299/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-of-dctn2-and-its-tumour-promoting-role-in-hcc-abstract/341299.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main research goal regarding DCTN2?","Question",{"text":112,"@type":113},"To comprehensively evaluate DCTN2 expression status and its potential functions across malignancies, and to clarify how it influences hepatocellular carcinoma progression and the tumour immune microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does DCTN2 expression relate to patient prognosis?",{"text":117,"@type":113},"Higher DCTN2 expression corresponds to poorer prognosis in tumour patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism did the study identify for DCTN2’s tumour-promoting effects in HCC?",{"text":121,"@type":113},"DCTN2 promotes tumour progression by modulating the AKT signalling pathway; DCTN2 knockdown reduces AKT phosphorylation and downstream targets, while AKT activation partially rescues the anti-tumour effects.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341299,1790916601,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","DOI: 10. 1111/jcmm.18450  \nOR I G I NAL ART I C L E  \nPan-cancer analysis of DCTN2 and its tumour-promoting role in HCC by modulating the AKT pathway  \nShuning Xu1 | Jiyuan Xing2 | Ke Li1 | Lei Qiao1 | Cheng Zhang1 | Yulin Ren1 | Ying Liu1   \n1Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China  \n2Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China  \nCorrespondence  \nYing Liu, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.  \nEmail: [zlyyliuying1664@zzu.edu.cn](zlyyliuying1664@zzu.edu.cn)  \nAbstract  \nDynactin subunit 2 (DCTN2) has been reported to play a role in progression of several tumours; however, the involvement of DCTN2 in potential mechanism or the tumour immune microenvironment among various cancers still remains largely unknown. Therefore, the objective of this study was to comprehensively investigate the expression status and potential function of DCTN2 in various malignancies through different database, such as The Cancer Genome Atlas, the Genotype-Tissue Expression and Gene Expression Omnimus databases. We discovered that DCTN2 expression was high in many type of tumours tissues compared to adjacent non-tumour ones. High DCTN2 signified poor prognosis for patients with tumours. Additionally, Gene Set Enrichment Analysis (GSEA) analysis revealed that DCTN2 was positively correlated with oncogenic pathways, including cell cycle, tumour metastasis-related pathway, while it was negatively with anti-tumour immune signalling pathway, such as INF-γ response. More importantly, we elucidated the functional impact of DCTN2 on hepatocellular carcinoma (HCC) progression and its underlying mechanisms. DCTN2 expression was much higher in HCC tissues than in adjacent non-tumour tissues. Silencing DCTN2 dramatically suppressed the proliferative and metastasis capacities of tumour cell in vitro. Mechanistically, DCTN2 exerted tumour-promoting effects by modulating the AKT signalling pathway. DCTN2 knockdown in HCC cells inhibited AKT phosphorylation and its downstream targets as well. Rescue experiments revealed that the anti-tumour effects of DCTN2 knockdown were partially reversed upon AKT pathway activation. Overall, DCTN2 may be a potent biomarker signifying tumour prognosis and a promising therapeutic target for tumour treatment, particularly in HCC.  \nK E Y WO R D S  \nAKT pathway, dynactin subunit 2, hepatocellular carcinoma, pan-cancer  \n\n| Shuning Xu and Jiyuan Xing have contributed equally to this work and share first authorship. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Author(s) . Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. |\n\nJ Cell Mol Med. 2024;28:e18450 .  \n[https://doi.org/10.1111/jcmm.18450](https://doi.org/10.1111/jcmm.18450)  \n[wileyonlinelibrary.com/journal/jcmm](wileyonlinelibrary.com/journal/jcmm)  \n1 of 15  \n1 | INTRODUCTION  \nIn recent years, there has been a progressive upsurge in cancer incidence, making it a principal global cause of mortality and imposing an overwhelming strain on the global healthcare system, such as the health and economic aspects.1 Despite continuous advancementsin treatment methods, surgical resection remains the most effective treatment modality. However, most patients are already in advanced stages of the disease when being diagnosed, missing the optimal treatment window and resulting in a need for improved overall survival rates. Recently, the emergence of immunotherapy holds promise in breaking this impasse.2 Immune checkpoint inhibitors have demonstrated substantial efficacy against various tumours, including haematological ma","cbCaio4LYTPwIdw9","https://ap.wps.com/l/cbCaio4LYTPwIdw9","pdf",18271256,15,"English","# Abstract\n## Introduction\n## Background and related work","[{\"question\":\"What is the main research goal regarding DCTN2?\",\"answer\":\"To comprehensively evaluate DCTN2 expression status and its potential functions across malignancies, and to clarify how it influences hepatocellular carcinoma progression and the tumour immune microenvironment.\"},{\"question\":\"How does DCTN2 expression relate to patient prognosis?\",\"answer\":\"Higher DCTN2 expression corresponds to poorer prognosis in tumour patients.\"},{\"question\":\"What mechanism did the study identify for DCTN2’s tumour-promoting effects in HCC?\",\"answer\":\"DCTN2 promotes tumour progression by modulating the AKT signalling pathway; DCTN2 knockdown reduces AKT phosphorylation and downstream targets, while AKT activation partially rescues the anti-tumour effects.\"}]","Pan-cancer analysis of DCTN2 and its tumour-promoting role in HCC - Abstract | PDF",1790041404,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/655d22b52af76f995bdca3dfc762034e.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68e37b0f59fa85f4649051b953032a5c.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cb961a2e61ba08841c413d3fff8fe7c.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82ce3f1f4f58654ae192ca678e6e9815.webp",980,1287]